Autorisation d’accès précoce refusée à la spécialité QALSODY (tofersen) dans l’indication « traitement des adultes atteints de sclérose latérale amyotrophique (SLA) associée à une mutation du gène superoxyde dismutase 1 (SOD1) ».
See also
HAS opinions and decisions
22/10/2024
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
k80hgf4z6uPcPDqt
